Anti CD19/CD22 chimeric antigen receptor T cell therapy - Yake Biotechnology
Alternative Names: CD19/CD22 CART cell therapy - Yake BiotechnologyLatest Information Update: 28 Apr 2024
Price :
$50 *
At a glance
- Originator Yake Biotechnology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Precursor B-cell lymphoblastic leukaemia-lymphoma
- No development reported Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for clinical-Phase-Unknown development in Chronic-lymphocytic-leukaemia in China (Parenteral)
- 28 Apr 2024 No recent reports of development identified for clinical-Phase-Unknown development in Non-Hodgkin's-lymphoma in China (Parenteral)
- 09 Dec 2023 Efficacy and adverse events data from a phase II trial in Precursor B-cell lymphoblastic leukaemia-lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)